NNovo Nordisk Read More Novo’s CagriSema delivers superior weight loss versus2026-09-22 CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4%* versus tirzepatide 5 mg of 9.1%* and non-inferior…
NNovo Nordisk Read More Novo Nordisk’s Pipeline Humming, but Shares Remain Stuck in Neutral2026-06-06 Novo Nordisk shares slip 4.35% as pipeline advances—Zenagamtide Phase-3 set, Wegovy combo deal with Veru, and oral Wegovy…
NNovo Nordisk Read More Novo Nordisk’s new weight loss treatment inferior to tirzepatide 2026-02-27 Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to…
NNovo Nordisk Read More Novo Nordisk’s triple agonist delivers up to 19.7% weight loss2026-02-26 Novo Nordisk’s triple agonist UBT251 delivered a mean weight loss of 19.7% after 24 weeks in a Phase…